Beyond arterial remodelling: Pulmonary venous and cardiac involvement in patients with systemic sclerosisassociated pulmonary arterial hypertension

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 6-8

  Dorfmuller P ^a,b,c   Montani, D ^a,b,c   Humbert, M ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PROSTACYCLIN; PROSTANOID; VASODILATOR AGENT;

ARTERY RECONSTRUCTION; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL OCCLUSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; EDITORIAL; EMBOLISM; FIBROSING ALVEOLITIS; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG HEMORRHAGE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY ARTERIAL REMODELLING; PULMONARY HYPERTENSION; PULMONARY VEIN; SARCOIDOSIS; SURVIVAL; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC;

EID: 75149162575     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00081009     Document Type: Editorial

References (34)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
3. Humbert M, Simonneau G. Survival in patients with idiopathic, familial and anorexigen-associated pulmonary arterial hypertension in the modern management era. Eur Respir J 2009; 34: Suppl. 53, 700s.
4. Sanchez O, Humbert M, Sitbon O, et al. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-277.
5. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
6. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050.
7. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000; 132: 425-434.
8. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004; 3: 339-352.
9. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-1340.
10. Humbert M, Simonneau G. Drug insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheum 2005; 1: 93-101.
11. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and longterm epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13: 1351-1356.
12. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189-200.
13. Rabiller A, Jaïs X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006; 27: 108-113.
14. Montani D, Jaïs X, Dorfmüller P, et al. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009; 34: 1204-1206.
15. Montani D, Jais X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009; 34: 1348-1356.
16. Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34: 371-379.
17. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893-902.
18. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35: 95-104.
19. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-1494.
20. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48: Suppl. 3, iii45-iii48.
21. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735-1743.
22. Moertl D, Berger R, Struck J, et al. Comparison of midregional proatrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009; 53: 1783-1790.
23. von Haehling S, von Bardeleben RS, Kramm T, et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 2009; [Epub ahead of print DOI: 10.1016/j.ijcard.2009.04. 019].
24. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
25. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-b receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2008; 20: 713-719.
26. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-206.
27. Dorfmüller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
28. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: Suppl. 1, S10-S19.
29. Tanaka E, Harigai M, Tanaka M, et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282-287.
30. Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
31. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531.
32. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medecine (Baltimore) 2008; 87: 220-233.
33. Palazzini M, Manes A. Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension. Eur Respir Rev 2009; 18: 177-180.
34. Vachiéry JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-169.